Clinical bottom line
Pharmacological interventions remain essential for managing gestational diabetes mellitus (GDM) when lifestyle modifications alone fail to achieve glycemic targets. Insulin continues to be the gold standard due to its safety profile and efficacy, but oral agents such as metformin and glyburide are increasingly used with growing evidence supporting their effectiveness and safety. Recent systematic reviews and meta-analyses suggest that pharmacological treatment improves maternal glycemic control and reduces adverse perinatal outcomes compared to conservative management alone. However, long-term metabolic outcomes for both mother and offspring require further study to optimize treatment strategies (Burch et al., 2020; Ikwuanusi et al., 2025).
What the evidence shows
Burch et al. (2020) summarize Cochrane evidence indicating that pharmacological interventions, primarily insulin and oral hypoglycemics, reduce the risk of macrosomia, shoulder dystocia, and neonatal hypoglycemia compared to diet alone. Insulin remains the preferred agent due to its established safety, but metformin has demonstrated comparable efficacy with the advantage of oral administration and less maternal weight gain.
Ikwuanusi et al. (2025) conducted a systematic review and meta-analysis comparing conservative (diet and lifestyle) versus pharmacological management in GDM. Their findings confirm that pharmacological treatment significantly improves glycemic control and reduces cesarean delivery rates and neonatal intensive care admissions, although heterogeneity in study designs and populations limits definitive conclusions.
Sedigheh Nouhjah et al. (2017) highlight that pharmacological treatment during pregnancy may influence postpartum metabolic outcomes, with some evidence suggesting metformin use is associated with improved insulin sensitivity after delivery.
Khan et al. (2022) provide a comprehensive review of both pharmacological and non-pharmacological interventions, emphasizing the importance of individualized treatment plans balancing efficacy, safety, and patient preference.
Dubois et al. (2025) reinforce that non-pharmacological strategies remain foundational but often require supplementation with medication to achieve optimal glycemic targets.
Caveats and uncertainty
Long-term safety data on oral hypoglycemic agents in pregnancy and their effects on offspring remain limited.
Variability in diagnostic criteria, treatment thresholds, and pharmacologic regimens across studies complicates direct comparisons.
Potential maternal side effects, such as gastrointestinal intolerance with metformin, and rare neonatal hypoglycemia with glyburide, warrant careful monitoring.
Optimal timing for initiation and choice of pharmacologic agent should consider patient-specific factors including severity of hyperglycemia and comorbidities.
Further research is needed to clarify postpartum metabolic trajectories and inform follow-up care.
How this may change practice
Clinicians should continue to prioritize lifestyle modification but recognize the need for timely pharmacological intervention when glycemic targets are unmet.
Metformin may be considered a first-line oral agent in appropriate patients, offering convenience and favorable maternal outcomes, with insulin reserved for more severe cases or when oral agents are contraindicated.
Multidisciplinary care involving endocrinologists, obstetricians, dietitians, and diabetes educators is critical to optimize maternal and neonatal outcomes.
Postpartum follow-up should include metabolic risk assessment and counseling to mitigate future diabetes risk.
Ongoing appraisal of emerging evidence will guide refinement of pharmacological protocols and personalized treatment strategies.